At least after all this cash shouldn't be an issue going forward if the company can pull out some strong announcements over the coming couple of years and raise the shareprice as the option conversions will keep the company in money despite what sales may occur (& probably more money then we need based on current spend). That and grants, R&D credits, and growing sales. And the company remains ours, although there will be more dilution but at least its dilution we know about. But at least the threat of more raises should be removed now and if institutions want in it will need to be on market. If the shareprice can reach 3.5c by May next year and 5c by May 2026 and better still 6.5c by Sep26 - we should be flush with cash
Starting position $13.3m proforma cash after current raise and R&D
148m existing options converted at 3.5c due May25 will bring in $5.2m cash
Do that again May26 with the 2nd tranche at 5c and you have another $7.4m cash
R&D credits next year say another $2.4m and 2026 $2.4m
SII sales $0.5m per year
Grant 1 $1.4m over 18 months Grant 2 $4.0m over 3 years - so probably at least $1.5m in grant recognition a year (depending on acquittals)
There's also another 44.5m existing options at 4.8c due Nov26 bringing in $2.1m and potentially 73m existing options at 6.4 due Sep26 bringing in $4.6m
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)